Detalhe da pesquisa
1.
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3.
Ann Oncol
; 2024 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38729566
2.
ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5).
Ann Oncol
; 33(11): 1097-1118, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35934170
3.
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Ann Oncol
; 32(10): 1245-1255, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34224826
4.
ESO-ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4).
Ann Oncol
; 31(6): 674-696, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32199930
5.
Reply to the Letter to the Editor 'There is no place for ovarian cancer screening in hereditary breast-ovarian cancer syndromes (in regard to "ESMO Clinical Practice Guideline on risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes")' by W. Tjalma.
Ann Oncol
; 35(1): 139-140, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37898238
6.
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
Ann Oncol
; 30(5): 766-773, 2019 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30796821
7.
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.
Ann Oncol
; 30(3): 397-404, 2019 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30475950
8.
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Ann Oncol
; 35(2): 159-182, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38101773
9.
Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.
Ann Oncol
; 34(1): 33-47, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36307055
10.
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Ann Oncol
; 29(7): 1541-1547, 2018 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29718092
11.
Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.
Ann Oncol
; 27(6): 1029-1034, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26961151
12.
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.
Ann Oncol
; 32(12): 1475-1495, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34678411
13.
Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations.
Breast Cancer Res Treat
; 157(3): 511-6, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27225387
14.
Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines.
Ann Oncol
; 31(12): 1664-1678, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32976936
15.
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).
Ann Oncol
; 31(12): 1623-1649, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32979513
16.
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.
Br J Cancer
; 111(6): 1132-8, 2014 Sep 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-25072261
17.
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Ann Oncol
; 30(11): 1842, 2019 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31407010
18.
Rates of risk-reducing surgery in Israeli BRCA1 and BRCA2 mutation carriers.
Clin Genet
; 85(1): 68-71, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23517234
19.
BRCA 1 and 2 mutation status: the elephant in the room during oncofertility counseling for young breast cancer patients.
Ann Oncol
; 29(1): 26-28, 2018 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29216337
20.
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4).
Ann Oncol
; 29(8): 1634-1657, 2018 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30032243